Windlas Biotech shares have gained nearly 9% in the last three months. SEBI-registered analyst Finkhoz is bullish on the stock, driven by its improving fundamental strength and a bullish chart setup.

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

In biotech, capital is a lifeline. Scientific progress alone doesn’t bring therapies to patients; sustained funding helps. With long development timelines and high burn rates, biotech companies must ...